…the Stand Up to Cancer (SU2C) multiple myeloma “dream team” — a multidisciplinary, inter-institutional group focused on addressing critical problems in multiple myeloma prevention, diagnosis, and treatment. It aims to…
…coverage, may play a role. What is multiple myeloma? Multiple myeloma is a cancer of the bone marrow involving plasma cells, which are mature white blood cells that produce antibodies….
…multiple myeloma. The researchers study two precursor conditions of multiple myeloma: Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). MGUS is a pre-malignant condition in which an…
…As the population of myeloma cells in the bone marrow expands, fewer red blood cells, white blood cells, and platelets are produced. Symptoms of multiple myeloma Sometimes, multiple myeloma does…
…well as blocking the pathways that trigger these interactions, which include both novel agents (so-called small molecules) and monoclonal antibodies. Read more: What is Multiple Myeloma? A History of Multiple…
As head of a family that includes seven children and 12 grandchildren, Susan Voigt says she is used to putting other people first. When it comes to trailblazing multiple myeloma…
…Correlative Science at Dana-Farber’s Jerome Lipper Center for Multiple Myeloma. A cell being attacked and killed by CAR cells. CAR T-cell therapy is a form of immunotherapy. Immunotherapies for myeloma…
…with multiple myeloma for 20 years. Bond credits Dana-Farber’s clinical trials for his longevity. Multiple myeloma leaders Paul Richardson, Nikhil Munshi, and Ken Anderson (left to right) Multiple myeloma is…
…the Jerome Lipper Multiple Myeloma Center at Dana-Farber. An illustration of multiple myeloma cells. Since 2006, when physicians adopted uniform international standards for monitoring patients with multiple myeloma and gauging…
For many patients with multiple myeloma, a new generation of drugs and drug combinations is producing better outcomes and fewer side effects. In recent months, several novel therapies studied and…
Multiple myeloma cells. Thanks to major advances in treatment in recent years, patients diagnosed with multiple myeloma today have a much greater life expectancy, even though the blood cancer isn’t…
…myeloma cells, predict poorer outcome and shorter survival, says Nikhil Munshi, MD, director of basic and correlative sciences at Dana-Farber’s Jerome Lipper Multiple Myeloma Center. Some of those higher-risk genetic…
…in multiple myeloma patients overall,” says Richardson, clinical director for the Dana-Farber/Brigham and Women’s Cancer Center Jerome Lipper Center for Multiple Myeloma, and the R.J. Corman Professor of Medicine, Harvard…
…improved treatment for multiple myeloma over the past three decades. For the past two decades, much of that work has taken place at the Jerome Lipper Multiple Myeloma Center and…
…for controlling promoters and enhancers in multiple myeloma. The finding may, on the one hand, help explain why myeloma often rebounds after drug treatment (therapies that stymie just one control…
…to clinical trial Cefalo was initially diagnosed with smoldering multiple myeloma, an early form of the condition that typically leads to active myeloma — especially in patients potentially at high risk…
In 2022, the drug teclistamab became the first bispecific antibody to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of multiple myeloma. Experts say the…
…the Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute, which had long partnered in her care. Trial participants were receiving CAR T-cell therapy,…
…the same time; relieved that the treatment would arrest progression of myeloma,” recalls Palayoor. Working towards a single goal While multiple myeloma is not curable, it can be managed with…
…College, Marathons and Multiple Myeloma What is Multiple Myeloma? Even though my dad is no longer with us, this story doesn’t have an end. Sometimes the conversations are hard, but…